Immunotherapy can be used for a larger number of patients, the main indication being expressing the PD-L1 biomarker in more than 50% of tumoral cells, but some literature has observed that PD-L1 is an imperfect biomarker and that immunotherapy only produces a response in the tumours of a minority of patients for whom it is indicated (Doroshow et al., 2019). Here, CD274 is linked to neoplasm.